PAR 20.4% 32.5¢ paradigm biopharmaceuticals limited..

Ann: Hay Fever Trial Update, page-2

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 739 Posts.
    lightbulb Created with Sketch. 1
    As a veterinarian, I was attracted by the use of PPS in humans (finally, as we have been using it in animals for more than 10yrs for arthritic conditions very successfully) in joint disease. It's use in allergic disease such as rhinitis was novel to me and whilst it showed strong efficacy in P1 trial, the formulation will have to be adjusted to move effectively deliver PPS to the target cells in the nasal passages to control symptoms.....so whilst it's use in treating diseases such as allergic rhinitis may or may not be possible depending on formulation, I am very confident of it's use in treating joint inflammation in people. I am in the process of applying to TGA under the Special Access Scheme for PPS for my wife's father for his knee whilst he waits for a joint replacement as he suffers considerable knee pain which currently only controlled by a combination opiod and nsaid medication,

    Kind regards, SEAH.
 
watchlist Created with Sketch. Add PAR (ASX) to my watchlist
(20min delay)
Last
32.5¢
Change
0.055(20.4%)
Mkt cap ! $82.30M
Open High Low Value Volume
27.5¢ 33.5¢ 27.5¢ $1.328M 4.323M

Buyers (Bids)

No. Vol. Price($)
1 4624 32.5¢
 

Sellers (Offers)

Price($) Vol. No.
33.0¢ 152597 4
View Market Depth
Last trade - 16.10pm 22/11/2024 (20 minute delay) ?
PAR (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.